Google (NASDAQ:GOOGL) (NASDAQ:GOOG) has begun its newest project what might be its most ambitious and difficult science project ever, reports The Wall Street Journal. The project, known as Baseline Study, seeks to create the fullest picture of what a healthy human being should be like. Dr. Andrew Conrad, a 50-year-old molecular biologist who pioneered cheap, high-volume tests for HIV in blood-plasma donations, is the key person in running the project.
As we said in our original analysis, collecting and aggregating health-related data from fitness tracking devices and health-related apps are what Google is focusing on. Although many other mass medical and genomics studies already exist, Google's Baseline Study will amass a much larger and broader set of new data. The company believes that without this kind of data, it would be impossible to develop effective prophylactic medicines. Google's aim is to help researchers detect killer diseases such as heart disease and cancer far earlier, so that they can be treated with those prophylactic medicines.
Dr. Conrad said, "With any complex system, the notion has always been there to proactively address problems." He continued to add, "That's not revolutionary. We are just asking the question: If we really wanted to be proactive, what would we need to know? You need to know what the fixed, well-running thing should look like." Indeed, without knowing how a healthy human being looks like, it's not entirely possible to help researchers detect killer diseases and develop preventive solutions. Dr. Conrad admits that the project is a giant leap into the unknown, but for investors in the evolving mHealth industry, Google's new project is undoubtedly an encouraging development. To learn more about Google's prospects in mHealth, read our original article.
Business relationship disclosure: The update has been written by a BB Research stock analyst. BB Research is not receiving compensation for it (other than from Seeking Alpha). BB Research has no business relationship with any company whose stock is mentioned in this article.
Disclosure: The author has no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. The author wrote this article themselves, and it expresses their own opinions. The author is not receiving compensation for it (other than from Seeking Alpha). The author has no business relationship with any company whose stock is mentioned in this article.